MYGN Reports $200.4M Q1 Rev, $34.1M Net Loss, $0.36 EPS, +2% YoY Rev, 68.7% Gross Margin, FDA Approves MyChoice CDx Companion, Launches Precise MRD, Cancer Care Continuum +13% Vol, $120.2M Rev, $124.4M Cash
Myriad Genetics Inc · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · Now $4.28
-28% in 7d after detection
Post-detection moves
1h
—
1d
-18%
3d
-15%
7d
-28%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS